

Cover Story
Conversation with The Cancer LetterFree
“The notion that cancer's not one disease, but thousands of diseases is really starting to sink in, and the implications of that fact are being felt throughout [NCI], and it means we have to change how we do everything. I hope that the early days of the Sharpless administration will be remembered as a time when we really bought into that reality and did some things differently,” NCI Director Norman “Ned” Sharpless said in a conversation with The Cancer Letter.
In Brief
Clinical Roundup
NCI Trials


NCI trials for February
NCI trials for FebruaryThe National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Trump cuts IVF drug deal with Merck in exchange for tariff exemption
- Science advocates organize march in DC to demand impeachment of RFK Jr.
- Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
ctMoniTR project aims to improve efficiency in development of intermediate endpoints - Experts warn that loss of carcinogen surveillance threatens to increase cancer incidence















